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Abstract
Study Objectives: This study examined how glucose, glucose regulatory hormones, insulin sensitivity, and lipoprotein
subclass particle concentrations and sizes change with sleep restriction during weight loss elicited by calorie restriction.
Methods: Overweight or obese adults were randomized into an 8-week calorie restriction intervention alone (CR, n = 12;
75% female; body mass index = 31.4 ± 2.9 kg/m2) or combined with sleep restriction (CR+SR, n = 16; 75% female; body mass
index = 34.5 ± 3.1 kg/m2). Participants in both groups were given the same instructions to reduce calorie intake. Those in
the CR+SR group were instructed to reduce their habitual time-in-bed by 30–90 minutes 5 days each week with 2 ad libitum
sleep days. Fasting venous blood samples were collected at pre- and post-intervention.
Results: Differential changes were found between the two groups (p = 0.028 for group × time interaction) in glucagon
concentration, which decreased in the CR group (p = 0.016) but did not change in CR+SR group. Although changes in mean

Statement of Significance
This study adds important information to the literature regarding the effects of sleep restriction in the context of calorie
restriction on health outcomes. The 8-week intervention used in this study is longer than many other controlled studies
examining sleep restriction. Another feature of the study is that sleep restriction was on 5 days a week (≤90 minutes per
day), and ad libitum sleep was on the other 2 days. Thus, the study design allows the results to have greater generalizability to populations in real life. Differential changes were found in serum glucagon concentrations between the groups
undergoing calorie restriction with and without sleep restriction. Results also suggest differential changes in mean HDL
particle size and visfatin concentration between the groups.
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HDL particle (HDL-P) size and visfatin concentration were not statistically different between groups (p = 0.066 and 0.066
for group×time interaction, respectively), mean HDL-P size decreased only in the CR+SR group (Cohen’s d = 0.50, p = 0.022);
visfatin concentrations did not change significantly in either group but appeared to decrease in the CR group (Cohen’s
d = 0.67, p = 0.170) but not in the CR+SR group (Cohen’s d = 0.43, p = 0.225).
Conclusion: These results suggest that moderate sleep restriction, despite the presence of periodic ad libitum sleep,
influences lipoprotein subclass particles and glucose regulation in individuals undergoing calorie restriction.
Clinical trial registration: ClinicalTrials.gov (NCT02413866, Weight Outlooks by Restriction of Diet and Sleep)
Key words: sleep restriction; catch-up sleep; weight loss; lipoprotein particles; glucagon; visfatin

An estimated 71.6% of adults in the United States are classified
as overweight or obese [1]. Excess adiposity is known to increase
the risk for the development of impaired glucose metabolism,
insulin sensitivity, and lipoprotein cholesterol profile [2, 3], and
to increase the risk for diabetes and cardiovascular diseases [4,
5]. Weight loss, even a modest amount, improves glucose metabolism and insulin sensitivity [6]. Weight loss also improves
traditional lipoprotein cholesterol profile, which includes
total cholesterol, low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), and triglyceride
(TG) concentrations [7, 8]. However, lipoprotein particles are
heterogeneous consisting of particles of a variety of sizes, with
smaller particles carrying less cholesterol. LDL particle (LDL-P)
concentration was a better indicator of atherosclerotic risk and
peripheral artery disease than LDL-C in large-scale studies [9–
11]. Low concentrations of HDL particles (HDL-P) were revealed
to be superior to low HDL-C in terms of cardiovascular risk prediction [12]. Low mean HDL-P size was also associated with
cardiovascular disease which may be secondary to the associations of HDL-P and HDL-C numbers to cardiovascular disease
[12]. Reductions in small very-low-density lipoprotein particle
(VLDL-P) concentration was found to be associated with reductions in atherosclerotic cardiovascular disease, independent of
LDL-C [13]. As such, lipoprotein subclass particle concentrations
and sizes are potentially better predictors of cardiovascular disease risks than traditional lipoprotein cholesterol profile. Few
studies have examined the impact of weight loss on lipoprotein
particle concentrations or sizes, and their results suggest that
LDL-P size increased following weight loss [14, 15].
Insufficient sleep has also been found to influence glucose
metabolism and insulin sensitivity [16–18]. Previously, glucose
tolerance and insulin sensitivity were reduced after several
nights of 4–5 hours of time-in-bed (TIB) per night compared to
≥8.5 hours TIB [19, 20]. More recent evidence showed that even
an average of one-hour sleep restriction on three consecutive
nights reduced insulin sensitivity compared to after three consecutive nights of ad libitum sleep [21]. Further, Depner et al.
[22] reported that a weekend of recovery sleep did not prevent
the reduced insulin sensitivity associated with recurrent insufficient sleep of two nights. These studies suggest that a short
period of daily sleep restriction adversely affects glucose metabolism and insulin sensitivity. However, Zielinski et al. found no
changes in glucose tolerance after 8 weeks of 90 minutes TIB restriction per night [23]. Thus, over a longer-period, the effects of
sleep restriction on glucose metabolism and insulin sensitivity
might be different from that of a short period.
Lipoprotein cholesterol profile has also been found to be associated with sleep duration. Shorter than 6 hours of sleep per

night and longer than 8 hours of sleep per night are associated
with higher total cholesterol, LDL-C, and TG concentrations, and
associated with lower HDL-C concentration [24, 25]. In population cohorts, individuals reporting insufficient sleep had lower
large HDL particle (HDL-P) concentrations than those reporting
sufficient sleep [26]. Studies have also shown that a few days of
sleep restriction influenced lipid metabolism [27, 28], and decreased small, medium, and large LDL-P, and small very-lowdensity lipoprotein particle (VLDL-P) concentrations [26].
The effects of sleep restriction during weight loss on glucose
metabolism and insulin sensitivity is less studied, and we are not
aware of published studies on changes in lipoprotein subclass.
Nedeltcheva et al. examined the effects of a 14-day hypocaloric
dietary weight loss program with two different sleep conditions,
5.5 hours of TIB and 8.5 hours of TIB [29]. Following the shortened sleep condition, fasting glucose and 24-hour average insulin concentration were significantly lower compared to the
longer sleep condition. St-Onge et al. studied normal-weight
adults following 4 hours of TIB and 9 hours of TIB over 5 consecutive nights while maintaining the same controlled diet [30].
Although the controlled diet was not designed to be hypocaloric,
participants lost a small amount of weight of approximately
0.9 kg on average following both conditions. No differences in
glucose or insulin concentrations were found between the sleep
conditions. The results of these two studies [29, 30] seem to be
different from those in the other abovementioned studies [17,
19–22], thus suggesting the effect of sleep restriction on glucose
metabolism and insulin sensitivity may be influenced by weight
loss. However, the durations of the sleep restriction intervention
in these studies were short (14 and 5 days, respectively), and the
effects of insufficient sleep on glucose metabolism and insulin
sensitivity in a longer-term sleep restriction intervention and in
the context of hypocaloric diet has not been studied.
Therefore, the aim of this exploratory study was to examine
the effects of moderate sleep restriction of less than or equal to
(≤) 90 minutes of nightly TIB during an 8-week calorie restriction program on glucose concentrations, insulin sensitivity,
hormones associated with glucose metabolism, and lipoprotein subclass particle sizes and concentrations in overweight
or obese adults. We hypothesized that sleep restriction during
calorie restriction would negatively impact glucose metabolism
compared to calorie restriction alone in overweight or obese
adults.

Methods
Data were obtained from the Weight Outlooks by Restriction
of Diet and Sleep (WORDS) study (ClinicalTrials.gov identifier:
NCT02413866). This study utilized a randomized controlled
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design to examine the influence of sleep restriction on outcomes associated with 8-week calorie restriction. Primary results on body composition have been previously described [31].
The study protocol was approved by the University of South
Carolina Institutional Review Board and all participants signed
an informed consent form prior to participation. Figure 1 shows
the sample sizes from the parent study to the present study,
which included 28 participants who had lipoprotein subclass
data at pre- and post-intervention. Of these participants, 23 also
had glucose regulatory hormone data available.

Participants were 35–55 years of age, overweight or obese [25 ≤
body mass index (BMI) ≤ 40 kg/m2], weight stable (≤3% body
weight change) during the previous 3 months and did not
smoke during the past year. No female participant was pregnant or lactating. None of the participants reported having
been diagnosed with diabetes; however, we did not purposely
screen for diabetes. Participants who were taking medications
had been taking those in a stable dose for >6 months prior to
participating in the study. Specifically, 4 participants reported
taking lipid or glucose-controlling medications. No participant
was a shift worker, nor had work that required long-distance
driving or operating heavy equipment. All participants reported
current 24-hour sleep duration was 6.5–8 hours, including naps
of <90 min/day, and no use of medications, devices, or hypnotics
to help sleep. Further, participants were assessed for sleep
apnea utilizing a WatchPat monitoring device (Itamar Medical,
Israel) at home for one night, and no one had signs of severe
sleep apnea (i.e. apnea-hypopnea index ≥ 30). All participants
were informed of potential safety issues associated with moderate sleep restriction during an individual orientation prior to
participation in the study.
Participants were randomized into one of two 8-week
interventions, calorie restriction alone or combined with
sleep restriction (CR and CR+SR, respectively), following preintervention measurements. The present study included 12 participants in the CR group and 16 in the CR+SR group (Figure 1).
During the intervention, all participants were asked to maintain

Figure 1. Participant flow diagram for the analytic sample.

normal daily activities and to not participate in other interventional research studies.

Calorie restriction
All participants were instructed to self-report all caloriecontaining items consumed, including any beverages or snacks,
for one week prior to the intervention, throughout the intervention, and 1 week after completion of the intervention.
Participants were instructed on using the MyFitnessPal application (MyFitnessPal, Inc.) that is available on smartphones
or web-based devices. If a smartphone or computer was unavailable, participants were provided with a self-report paper
form to record any calorie-containing food or drink consumed,
including portion size, calories, and macronutrient breakdown
(carbohydrate, protein, and fat) utilizing The Calorie King Calorie
Counter.
Each individual’s resting metabolic rate was measured, and
95% of this value was calculated and used as a daily calorie intake goal for each respective participant [31]. Prepackaged meals,
based on each participant’s calorie intake goals, were provided
for lunch and dinner 4 days each week during the intervention.
These meals also served as samples that meet the calorie intake goal for participants. Dietary instruction was provided to
each participant for breakfast and snacks throughout the day, as
well as during the 3 days of ad libitum food consumption when
participants were able to eat freely. Each week research staff collected the dietary records and reviewed with participants.

Sleep restriction
Participants wore an actigraphy monitor (ActiGraph GT3X+,
ActiGraph, Pensacola, FL) on their non-dominant wrist for a week
prior to the intervention, throughout the 8-week intervention, and
for a week after the intervention to evaluate sleep. Participants
were also instructed to maintain a sleep diary during these days recording time getting into bed, lights turned off and trying to sleep,
waking up, and getting out of bed, and any naps taken throughout
the day. Sleep diaries and actigraphy recordings were reviewed by
staff and any issue was discussed with the participant each week.
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Measurements
Height, body weight, and physical activity
Height was measured using a stadiometer at pre- and postintervention. Bodyweight, with participants wearing standard
scrubs, was measured at pre-intervention, weekly during intervention, and post-intervention using an electronic scale that
was calibrated annually (CC Vaughan & Sons, Incorporated,
Columbia, SC).
Previous evidence suggests that both hypocaloric diet and
sleep restriction could affect physical activity [40, 41], which
may subsequently affect glucose control and lipoprotein profile.
Thus, physical activity at pre- and post-intervention were quantified by the actigraphy monitor (ActiGraph GT3X+, ActiGraph,
Pensacola, FL) using manufactured provided software (Actilife
version 6.11). This monitor quantifies accelerations resulting
from physical activity-associated bodily motion at a fixed point
of the body to determine physical activity intensities. Physical

activity counts per minute per day were determined by combining the magnitude of sampled acceleration from all three
axes measured by the monitor as an integrated measure of
physical activity. Previously, physical activity counts measured
by the Actigraph GT3X+ worn on the wrist and on the waist
were found to be strongly correlated as a non-intensity specific
measure of physical activity [42] and was therefore included as
a measure of total physical activity.

Serum sample collection
Venous blood samples were collected in a BD serum Vacutainer
following a minimum of a 12-hour fast (not including water),
between 06:00 and 09:00 hours, at pre- and post-intervention.
Following approximately 30 minutes allowing the blood to clot,
the whole blood was centrifuged at 3000 rpm at 4°C for 20 minutes. Serum separated after centrifugation was aliquoted and
stored at −80°C until all participant samples were ready for
analysis.

Lipoprotein subclass particle concentrations and
sizes, and NMR-calculated values
Serum samples were analyzed by LipoScience, Inc. (Raleigh, NC)
for determination of lipoprotein subclass particle concentrations
and sizes by nuclear magnetic resonance (NMR) spectroscopy.
The LipoProfile-3 algorithm [43] was used to determine concentrations of small, medium, and large (including chylomicron)
very-low-density lipoprotein particle (VLDL-P) and HDL-P, small
and large LDL-P and intermediate-density lipoprotein particle
(IDL-P). Weighted-average VLDL-P, LDL-P, and HDL-P diameter
was calculated as the sum of the lipoprotein subclass diameters multiplied by its relative mass percentage as estimated
from the amplitude of its methyl NMR signal. Apolipoprotein B
(ApoB)-containing lipoprotein particles, including VLDL-P, IDLP, and LDL-P, possess atherogenic properties [44]; thus, ApoBcontaining lipoprotein concentration was calculated as the sum
of the three. Total TG and HDL-C concentrations were calculated
by NMR. In addition, a lipoprotein insulin resistance score (LPIR), an index for insulin sensitivity [45], was also calculated.

Glucose, glucose regulatory hormones and indices of
insulin sensitivity
Serum glucose concentrations were analyzed in duplicate samples using YSI 2300 STAT Plus (YSI Life Sciences, Yellow Springs,
OH), which was calibrated according to manufacturer instruction. A single Bio-Plex Pro Human Diabetes Panel 10-Plex assay
(BIO-RAD Laboratories, Hercules, CA) was used to analyze serum
concentrations in duplicate samples of insulin, glucagon, gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP1), visfatin and resistin using a MAGPIX system (Luminex
Corporation, Austin, TX) following manufacturer instruction.
Insulin and glucagon are hormones that regulate glucose concentrations. GIP and GLP-1 are incretins that stimulate insulin
secretion [46–48]. Visfatin mimics insulin [49] and resistin promotes insulin resistance [50].
The updated homeostasis model assessment of insulin resistance (HOMA2-IR) was calculated using the HOMA Calculator
program v2.2.3, which simulates the physiological processes
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For the CR+SR group, participants were directed to reduce
their total TIB by a minimum of 30 minutes and up to 90 minutes
on 5 nights per week, and to sleep freely on the other 2 nights
each week. To aid in retention and adherence to the CR+SR
group, each participant chose their own sleep restricted and ad
libitum sleep days, and allowed a range of TIB reduction between
30 and 90 minutes. Participants were instructed to achieve this
reduction by going to bed later, getting up earlier, or a combination of both, and maintaining their nap habits. Participants
were also asked to maintain their sleep schedule throughout
the 8-week intervention and to not shift nightly sleep schedules.
Participants in the CR only group were instructed to maintain
their daily sleep and nap habits throughout the study.
Output from the monitors was analyzed using the ActiLife
6.11 software program provided by the manufacturer. Minuteby-minute asleep/awake status was determined using the
Cole-Kripke Algorithm [32]. Self-reported times from the sleep
diary were entered into the ActiLife software program to help
quantify total sleep time (TST) and TIB for each participant.
TST was defined as the total number of minutes considered
asleep by the actigraphy device, while TIB was total time from
getting into bed with lights off trying to sleep until getting out
of bed plus any naps recorded by the participant throughout
the day. The difference in midpoint of nightly TIB during sleep
restricted days and ad libitum days for participants in the
CR+SR group was calculated. The difference in midpoint of
TIB on workdays and free days for those in the CR group was
also calculated.
To monitor adverse changes due to the intervention, all participants were asked to complete the Center
for Epidemiological Studies Depression Scale (CES-D) [33],
Epworth Sleepiness Scale (ESS) [34], Functional Outcomes
of Sleep Questionnaire (FOSQ) [35], Pittsburg Sleep Quality
Index (PSQI) [36], the 36-Item Short Form (SF-36) [37], and
Psychomotor Vigilance Test (PVT) [38, 39] at pre-intervention
and every 2 weeks during the intervention. Indications for exclusion from the study were set at clinical depression (CES-D
> 16), excessive sleepiness (ESS > 12), a change >10% in FOSQ,
or PVT response time >500 ms. No participant experienced
changes based on these criteria that would be considered exclusionary from the study.

Sparks et al. |
that influence circulating glucose and insulin levels in order to
provide model-derived estimates of insulin resistance [51, 52].
The quantitative insulin-sensitivity check index (QUICKI) was
calculated as 1/[log(I)+log(G)], where I and G were concentrations of fasting insulin and glucose, respectively [53].

Statistical analysis

Results
Participant characteristics
Participant characteristics prior to the intervention are shown
in Table 1. No differences between the CR and CR+SR groups for
age, sex or race composition, height, blood pressure, proportion
of participants having signs of mild or moderate sleep apnea,
calorie intake, or total physical activity were found. However,
body weight and BMI were significantly greater in the CR+SR
group compared to the CR group. This sub-sample was comparable in these characteristics to the full sample.
The CR and CR+SR groups had similar degree of calorie restriction compared to pre-intervention throughout the 8 weeks
(14.0 ± 9.2% and 17.8 ± 7.9%, p = 0.264). After the intervention,
body weight significantly decreased in both groups with no significant difference found in the amount of absolute or percent
weight loss between groups (p = 0.974 and 0.818, respectively).
The amount of weight loss in this sub-sample was also comparable to the full sample.
Total physical activity did not change differently between the
two groups from pre- to post-intervention (p = 0.454 for group
× time interaction). There was no significant change found in
physical activity within either the CR or CR+SR group (p = 0.132
and 0.500, respectively) or in the overall sample (p = 0.119).

Sleep duration, midpoint sleep time, and selfreported questionnaires and assessment
No differences in TIB, TST, or midpoint sleep time between CR
and CR+SR groups prior to intervention were found (Table 2).
For the CR+SR group, TIB and TST were shorter on the 5 days
when sleep was restricted, by 49 and 66 minutes on average,

respectively, and longer on the 2 ad libitum days, by 75 and 57
minutes on average, respectively, during the 8-week intervention compared to pre-intervention values. For the CR group, both
TIB and TST remained stable throughout the intervention. The
difference between midpoint sleep time on sleep-restricted days
and ad libitum sleep days for the CR+SR group was not different
from the difference in midpoint sleep on workdays and free
days for the CR group (p = 0.412).
Presented in Supplementary Table 1 are the scores of
self-administered questionnaires and assessments at preintervention and every 2 weeks throughout intervention. No participant in either the CR or CR+SR group had changes that met
the pre-determined criteria for exclusion during the intervention.

Lipoprotein subclass particle concentrations
and sizes
Fasting serum lipoprotein subclass particle concentrations and
sizes are found in Table 3. Prior to intervention, no significant
differences in any of the lipoprotein subclass particle concentrations or sizes were found between the CR and CR+SR groups (p ≥
0.187 for all), which persisted after adjusting for pre-intervention
body weight (p ≥ 0.141 for all).
Although the differences between the CR and CR+SR groups
in the changes in mean HDL-P size and TG concentration (NMRcalculated) were not statistically significant (p for group × time
interaction = 0.066 and 0.077, respectively), we further examined the changes within each group given the small sample
size and exploratory nature of the study. Mean HDL-P size decreased in the CR+SR group with medium effect size (Cohen’s
d = 0.50, p = 0.022), but did not change in the CR group (Cohen’s
d = 0.00, p = 0.790) (Figure 2). TG concentration did not change
significantly in either group and the effect sizes were small (CR:
Cohen’s d = 0.16, p = 0.078; CR+SR: Cohen’s d = 0.47, p = 0.269;
using transformed data).
All other NMR-determined concentrations and sizes did not
change differently from pre- to post-intervention between the
CR and CR+SR groups. After adjustment for pre-intervention
weight or weight change from pre- to post-intervention, the
changes in CR and CR+SR groups were not different for all lipoprotein subclass particle concentrations and sizes, and NMRcalculated variables (all p values for group × time interaction ≥
0.109).

Glucose, glucose regulatory hormones, and insulin
sensitivity indices
Fasting serum concentrations of glucose, insulin, glucagon, GLP1, GIP, visfatin, and resistin, and indices of insulin sensitivity
are presented in Table 4. Prior to the intervention, CR+SR had
a significantly higher insulin concentration and lower QUICKI
compared to the CR group (p = 0.029, and 0.027, respectively).
Glucose and the other glucose regulatory hormone concentrations, as well as HOMA2-IR index were not different (p > 0.059
for all). After adjustment for pre-intervention body weight, there
were no differences at pre-intervention between CR and CR+SR
groups for any of these concentrations or indices of insulin sensitivity (p ≥ 0.051 for all).
Differential changes from pre- to post-intervention in glucagon concentrations were found between the CR and CR+SR
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Statistical analysis was performed using SAS version 9.4 (Cary,
NC). The Shapiro-Wilk and Kolmogorov-Smirnov tests were performed to test whether the data were normally distributed. Nonnormally distributed data were transformed using log(10) to be
used in statistical models. Pre-intervention values were compared between CR and CR+SR using independent t-test or Chisquare test as appropriate. A general linear model with repeated
measures, including a group×time interaction, was utilized to
determine if any variables changed differently between the two
groups following their respective interventions. Pre-intervention
body weight or change in body weight was adjusted in the general linear models to account for potential influences of these
variables. Paired sample t-tests were performed within each
group to compare pre- and post-intervention values and effect
sizes (Cohen’s d and partial Eta Squared) were also calculated.
Change values were calculated by subtracting pre-intervention
values from post-intervention values. A p value of < 0.05 was
considered statistically significant.

5

6

| SLEEPO, 2020, Vol. 1, No. 1

groups. It significantly decreased in the CR group with a large
effect size of change (Cohen’s d = 0.93, p = 0.016), but did not
change in the CR+SR group with a small effect size of change
(Cohen’s d = 0.21, p = 0.701) (Figure 3). Glucagon concentration
changes were still different following adjustment for body
weight change from pre- to post-intervention (p for group ×
time interaction = 0.035). In each group, glucagon changes
were similar to without adjustment (CR: a large effect size
reflected by partial Eta Squared = 0.324, p = 0.054; CR+SR: a
small effect size reflected by partial Eta Squared = 0.010,
p = 0.765). Glucagon concentration changes were no longer

CR (n = 12)
Age (years)
44.8 ± 6.4
Sex (M/F)
3/9
Race (C/AA/H)
5/7
Height (m)
1.69 ± 0.05
31.4 ± 2.9
Body mass index (kg/m2)
Blood pressure, systolic
122.6 ± 8.5
(mmHg)
Blood pressure, diastolic
79.5 ± 4.1
(mmHg)
Apnea-Hypopnea Index†
6/3/3
<5 / ≥5 and <15 / ≥15
and <30 events per hour (n)
Calorie Intake (kcal/day)
Pre-Intervention
1642 ± 361
During intervention
1395 ± 257
Bodyweight (kg)
Pre-Intervention
89.2 ± 9.2
Post-Intervention
86.4 ± 8.8‡
Physical activity (counts/minute/day)
Pre-Intervention
1633 ± 371
Post-Intervention
1761 ± 414

CR+SR
(n = 16)*

p value

44.2 ± 5.5
4/12
7/8/1
1.71 ± 0.07
34.5 ± 3.1
125.3 ± 6.3

0.789
1.000
0.655
0.349
0.010
0.335

80.3 ± 5.6

0.699

8/5/3

0.840

1926 ± 545
1562 ± 379

0.144
0.216

100.8 ± 9.3
98.0 ± 9.9‡

0.003

1558 ± 301
1582 ± 413

0.556

Data presented as Mean ± SD. CR: calorie restriction; CR+SR: calorie restriction
and sleep restriction. C: Caucasian; AA: African American; H: Hispanic. Listed p
values are for comparisons between CR and CR+SR at pre-intervention. The p
values in bold are < 0.05.
*The subset of participants who also had glucose regulatory hormones data
(n = 11) had similar values to these reported here.
†
Assessed by WatchPat (Itamar Medical, Israel) home testing.
‡
p < 0.05 significant difference from pre- to post-intervention within the specific group.

Discussion
To our knowledge, this study is the first to examine the effects
of chronic moderate sleep restriction of ≤90 minutes TIB with
periodic ad libitum sleep during a calorie restriction weight loss
intervention in overweight or obese adults. The primary findings
are that there were differential changes in serum glucagon concentration between the CR and CR+SR groups, which decreased in
the CR group only. Additionally, mean HDL-P size decreased only
in the CR+SR group, and visfatin concentrations had a medium
effect size of reduction in the CR group but only a small effect
size of change in the CR+SR group. The changes in mean HDL-P
size and visfatin were not statistically different between the CR
and CR+SR groups, likely due to the small sample size. These data
suggest that allowing ad libitum sleep on 2 nights per week did
not prevent the differential changes in mean HDL-P size, and glucagon and visfatin concentrations between the CR and CR+SR
groups. These findings are in line with recent literature suggesting
that ad libitum sleep on the weekend did not prevent decreases in
insulin sensitivity induced by sleep restriction [22].

Table 2. Time in bed (TIB) and total sleep time (TST) at pre-intervention and during intervention, and midpoint sleep time by intervention
group
CR (n = 12)

Average TIB (min/day)
Sleep restricted days
Ad libitum sleep days
Average TST (min/day)
Sleep restricted days
Ad libitum days
Midpoint sleep time (HH:MM)
Sleep restricted or workdays
Ad libitum or free days

CR+SR (n = 16)

Pre-intervention

During intervention

Pre-intervention

During intervention

421.6 ± 67.2

422.3 ± 26.4

423.6 ± 75.0

372.9 ± 69.6

374.0 ± 49.3

367.9 ± 68.4

03:07 ± 00:51

03:13 ± 00:30
03:01 ± 00:35
03:24 ± 00:32

02:48 ± 01:23

408.9 ± 52.7
379.9 ± 7.0§
504.0 ± 18.0§
353.8 ± 47.4
314.1 ± 16.7*
437.2 ± 18.6*
03:16 ± 01:24
03:05 ± 01:29
03:27 ± 01:25

Data presented as Mean ± SD. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction.
*p < 0.01 compared to pre-intervention values; §p < 0.001 compared to pre-intervention values.
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Table 1. Participant characteristics by intervention group

different between the CR and CR+SR groups after adjustment for pre-intervention body weight (p for group × time
interaction = 0.262).
We also examined changes in visfatin concentration within
each group, considering the small sample size and a near significant group × time interaction (p = 0.066). Visfatin concentration did not change significantly in either group (p = 0.170
and 0.225, for CR and CR+SR, respectively, using transformed
data). However, it decreased with a medium effect size in the
CR group (Cohen’s d = 0.67) but increased with a small effect
size in the CR+SR group (Cohen’s d = 0.43) (Figure 4). After adjustment for pre-intervention body weight or weight change
from pre- to post-intervention, visfatin concentrations were still
near statistically different between the CR and CR+SR groups in
the changes after interventions (p for group × time interaction
=0.063 and 0.069, respectively).
The CR and CR+SR groups did not change differently from
pre- to post-intervention in concentrations of glucose, insulin,
GLP-1, GIP, or resistin, or any index of insulin sensitivity (all p
values for group × time interaction >0.123). Adjustment for preintervention body weight or weight change from pre- to postintervention did not influence these findings (all p values for
group×time interaction ≥0.140).
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Table 3. Lipoprotein subclass particle concentrations and sizes, and NMR-calculated values at pre- and post-intervention by intervention group
CR (n = 12)
Preintervention

HDL-C
LP-IR Score

1.96 ± 0.24
49.6 ± 18.6
44.8 ± 23.6

Group×Time interaction

Postintervention

Preintervention

Postintervention

43.2 ± 22.6
4.3 ± 3.5
0.47 ± 0.42
6.9 (0.6–26.9)
0.75 ± 0.44
30.8 ± 18.9

41.8 ± 16.7
3.6 ± 2.4
0.44 ± 0.37
7.6 (1.6–21.9)
0.76 ± 0.33
30.8 ± 13.2

48.8 ± 20.8
3.8 ± 1.7
0.53 ± 0.23
6.5 (0.2–29.8)
0.72 ± 0.51
36.8 ± 17.8

861 (685–1389)
2.97 ± 0.12
184 ± 130
361 ± 257
2.54 ± 0.36
431 ± 280
928 (730–1425)
2.99 ± 0.12

882 ± 240
2.93 ± 0.12
202 ± 85
184 (0.0–770)
2.39 ± 0.51
399 ± 165
923 ± 238
2.95 ± 0.11

925 ± 261
2.95 ± 0.14
184 ± 103
253 (0.0–758)
2.52 ± 0.38
453 ± 217
974 ± 272
2.97 ± 0.13

27.1 ± 8.1
6.8 ± 3.9
0.76 ± 0.28
8.1 ± 5.3
0.87 ± 0.31
12.2 ± 8.5

27.4 ± 11.5
7.4 ± 3.2
0.82 ± 0.22
7.3 (3.8–19.0)
0.91 ± 0.21
10.8 ± 7.9

26.5 ± 10.9
6.4 ± 3.0
0.76 ± 0.21
9.1 ± 4.4
0.91 ± 0.22
11.0 ± 9.0

49.5 ± 6.5
20.9 (19.7–21.5)
1.31 ± 0.01
9.7 ± 0.7

49.8 ± 5.9
20.7 ± 0.8
1.32 ± 0.02
9.9 ± 0.6

50.4 ± 7.2
21.0 (19.6–22.1)
1.32 ± 0.02
9.6 ± 0.6

91.4 ± 55.1

65.0 (24.0–
158.0)
1.85 ± 0.23
46.5 ± 22.3
40.4 ± 15.5

91.8 ± 40.4

1.88 ± 0.27
45.9 ± 19.4
43.3 ± 24.1

1.92 ± 0.20
43.2 ± 21.4
46.1 ± 17.0

p value

0.104
0.507†
0.450†
0.224

0.301†
0.662
0.289†
0.229
0.251†
0.883
0.927†
0.917†
0.552
0.506
0.491†
0.066

0.077†
0.941
0.202

Normally distributed data are presented as Mean ± SD; non-normally distributed data are presented as median (lower quartile-upper quartile) and log(10) transformed (mean ± SD) underneath. NMR: nuclear magnetic resonance; CR: calorie restriction; CR+SR: calorie restriction and sleep restriction; CHY-P/C: chylomicron
particle/cholesterol; VLDL-P/C: very-low-density lipoprotein particle/cholesterol; LDL-P/C: low-density lipoprotein particle/cholesterol; IDL-P: intermediate-density
lipoprotein particle; TG: triglyceride; Apo-B: apolipoprotein-B; HDL-P/C: high-density lipoprotein particle/cholesterol; LP-IR: lipoprotein insulin resistance
†
p value for test using transformed data.

Lipoprotein subclass particle concentrations
and sizes
Due to the small number of studies completed, how sleep restriction may affect the lipoprotein profile remain inconclusive.
Reynolds et al. found that TG concentration was lower following
five nights of 4-hour TIB compared to two nights of 10-hour TIB
in healthy weight adults [54]. However, O’Keeffe et al. found no
changes in total cholesterol, HDL-C, or TG concentrations following five nights of 4-hour TIB compared to 9-hour TIB in a randomized cross-over trial of young normal weight adults [55]. In
healthy adults undergoing five nights of 4-hour TIB compared
to controls achieving five nights of >7-hour TIB, small, medium,
and large LDL-P, small VLDL-P, and ApoB concentrations decreased with no changes in small, medium, or large HDL-P concentrations [26].
To date, we are not aware of any study that has examined
the influence of prolonged period of sleep restriction on lipoprotein profile. Aho at el. examined the putative effects of

prolonged insufficient sleep, assessed by self-report, using two
independent large sample epidemiologic cohorts [26]. They
found that large and extra-large HDL-P concentrations were
lower among individuals who reported subjective sleep insufficiency compared to individuals without subjective sleep
insufficiency. Our study found mean HDL-P size decreased in
the CR+SR group but not the CR group. Given that larger HDL-P
size is associated with lower cardiovascular disease risk [12],
these results suggest that lipoprotein profile was negatively
influenced by the addition of sleep restriction to calorie restriction in the CR+SR group when compared to CR weight loss
alone in overweight or obese adults.

Glucose, glucose regulatory hormones, and insulin
sensitivity indices
In our study, glucose and insulin concentrations did not have differential changes between the CR and CR+SR groups; however,
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CHY-P and VLDL-P Concentration (nmol/L)
Total CHY-P and VLDL-P
47.2 ± 19.1
Large CHY-P and VLDL-P
2.6 (0.5–11.2)
0.45 ± 0.45
Medium VLDL-P
10.6 ± 7.5
0.92 ± 0.33
Small VLDL-P
32.3 ± 18.9
LDL-P and IDL-P Concentration (nmol/L)
Total LDL-P
1008 ± 249
2.99 ± 0.11
IDL-P
217 ± 114
Large LDL-P
324 ± 241
2.36 ± 0.54
Small LDL-P
467 ± 276
Apo-B Containing Lipoprotein-P
1055 ± 255
Concentration (nmol/L)
3.01 ± 0.11
HDL-P Concentration (µmol/L)
Total HDL-P
28.5 ± 7.5
Large HDL-P
6.7 (3.3–13.6)
0.83 ± 0.22
Medium HDL-P
7.1 ± 4.6
0.84 ± 0.23
Small HDL-P
13.8 ± 8.6
Mean Particle Size (nm)
VLDL-P
50.7 ± 7.0
LDL-P
20.8 ± 0.8
1.32 ± 0.02
HDL-P
9.7 ± 0.8
NMR-calculated values (mg/dL)
TG
104.4 ± 56.0

CR+SR (n = 16)
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glucagon concentration decreased in the CR group but did not
change in CR+SR group. The two previous studies involving
sleep restriction during calorie restriction did not measure glucagon [29, 30]. St-Onge et al. did not find differences in fasting
or average glucose and insulin concentrations in the morning,
afternoon, or at night between two different sleep opportunities, 4-hour and 9-hour TIB, in normal weight men and women
[30]. Nedeltcheva et al. noted that during a 14-day combined exposure to hypocaloric diet and short sleep periods, lower levels
of fasting and 24-hour insulin concentrations following 5.5hours of sleep opportunity versus 8.5-hours were found in overweight individuals (BMI=27.4±2.0 kg/m2) [29]. These changes are
consistent with a state of reduced carbohydrate availability potentially induced by calorie restriction. The weight loss in their
study was similar with our study, ~3–4% weight loss. These two
studies did not suggest sleep restriction during a short period
of calorie deficit had adverse effects on glucose metabolism. In
contrast, our results suggest adverse effects of sleep restriction
during a longer calorie restriction intervention period in participants who had a higher BMI than participants in the two previous studies. These results are important given that calorie
restriction for a few weeks may be used more by obese individuals than overweight and normal weight individuals in order to
obtain health benefits.
Visfatin is an adipocytokine known to possess insulinmimetic properties, functions to activate insulin receptors, and
acts as a determinant of insulin resistance in obesity [49]. A previous study in middle-aged, obese females who slept less than 6
hours found higher circulating visfatin concentration and lower
insulin sensitivity compared to women who achieved adequate
sleep [56]. A two-month intervention was implemented in these
women to increase the amount of sleep achieved each night and
found that visfatin concentration decreased and insulin sensitivity increased. In our study, visfatin concentration decreased

Strengths and limitations
This study adds important information to the literature regarding the effects of sleep restriction in the context of calorie restriction on cardiometabolic health outcomes. Very few
studies have examined outcomes in this nature, and, to our
knowledge, this study has been the only study completed examining a sleep restriction intervention lasting several weeks.
This 8-week study duration is considerably longer than other
controlled studies examining sleep restriction. Our study was
unique in that it involves modest sleep restriction, an average of
less than 90 minutes per day shorter TIB on 5 days a week, and
ad libitum sleep on the other 2 days of the week. By allowing participants to choose restricted sleep days make the results more
generalizable to the larger populations where catch-up sleep occurs throughout the week. In addition, the average difference in
midpoint sleep on sleep restricted days and ad libitum days in
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Figure 2. Mean high-density lipoprotein particle (HDL-P) size at pre- and postintervention by intervention group. Error bars represent standard error of the
mean. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction.
*p = 0.066 for group×time interaction. **p = 0.022 for pre- to post-intervention
comparison within CR+SR group.

in the CR group with medium effect size, suggesting the nonsignificant finding in this group was likely due to the small
sample size. These results are in line with previous study findings that sleep restriction potentially increases visfatin concentrations. However, no differential changes were found between
CR and CR+SR groups in insulin sensitivity from pre- to postintervention, as indicated by their similar changes in HOMA2-IR,
QUICKI, and LP-IR.
A few explanations exist for the lack of differential changes
in insulin sensitivity from pre- to post-intervention between
the CR and CR+SR groups. One reason is the influence of recent
nights’ sleep. Previously, insulin sensitivity is influenced by only
2–3 nights of restricted or extended sleep [21, 57]. We did not
control the last 2–3 nights’ sleep duration before blood sampling
in our study, as the CR+SR group chose their restricted and ad
libitum sleep days. Therefore, we were not able to determine if
any chronic effect due to the 8-week intervention that occurred
was influenced by recent nights’ sleep. These data suggest that
any influence of chronic moderate sleep restriction with periodic ad libitum sleep on insulin sensitivity, compared to the
effect of weight loss, was not substantial. Second, similar to the
study performed by Zielinski et al. [23], the possibility remains
that the duration of the intervention may have allowed for
chronic adaptations to occur due to sleep restriction. Lastly, the
degree of sleep restriction in our study may not be large enough
to influence insulin sensitivity.
The way in which accessory glucose regulatory hormones,
such as GIP, GLP-1, and resistin, relate to sleep restriction during
calorie restriction has yet to be elucidated. GIP is an incretin
which stimulates insulin secretion but does not inhibit glucagon
secretion and is known to be elevated in individuals with impaired glucose metabolism [47]. GLP-1 is another incretin that
stimulates glucose-dependent insulin secretion when plasma
glucose concentration is high, but not when plasma glucose
concentration falls below a normal range [46, 48]. Lastly, resistin,
an adipocytokine, is altered in obese adults [50]. The study by
St-Onge et al. found no differences in fasting GLP-1 following
4-hour vs. 9-hour TIB with a controlled diet [30]. Thus, our findings are in line with previous results suggesting that fasting
GLP-1 concentration may not be directly influenced by modest
weight loss in the presence or absence of moderate sleep
restriction.
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Table 4. Glucose, its regulatory hormones, and indices of insulin sensitivity at pre- and post-intervention by intervention group
CR (n = 12)

Glucose (mg/dL)
Insulin (uU/mL)
Glucagon (ƥg/mL)
GLP-1 (ƥg/mL)
GIP (ƥg/mL)

Resistin (ƥg/mL)
HOMA2-IR
QUICKI

Group×time interaction

Pre-intervention

Post-intervention

Pre-intervention

Post-intervention

p value

76.3 ± 16.6
6.6 (0.8–31.7)
0.77 ± 0.43
1776 (1428–2631)
3.26 ± 0.07
231 ± 95
2.34 ± 0.16
367 (260–819)
2.61 ± 0.17
5513 ± 2462
3.71 ± 0.18
5677 (2845–22092)
3.82 ± 0.25
1.25 (0.42–4.15)
0.05 ± 0.32
0.39 ± 0.08

74.4 ± 17.1
5.3 (1.8–24.4)
0.78 ± 0.32
1823 ± 317
3.18 ± 0.07
185 ± 70
2.16 ± 0.46
322 ± 70
2.50 ± 0.10
4161 ± 1405
3.59 ± 0.16
5515 (3496–13999)
3.81 ± 0.21
0.73 (0.52–3.27)
0.05 ± 0.26
0.39 ± 0.05

91.6 ± 20.1
15.6 ± 8.4ǂ
1.13 ± 0.26
1789 ± 243
3.25 ± 0.06
186 ± 41
2.26 ± 0.11
382 ± 135
2.56 ± 0.15
3883 ± 1659
3.55 ± 0.20
5802 ± 1478
3.75 ± 0.12
1.89 (0.49–4.17)
0.23 ± 0.27
0.32 ± 0.04ǂ

82.5 ± 17.4
13.9 (3.3–44.3)
1.05 ± 0.34
1771 ± 278
3.24 ± 0.07
154 (87–525)
2.25 ± 0.22
349 (149–2223)
2.57 ± 0.31
3992 (1377–15772)
3.66 ± 0.27
5718 (3312–23666)
3.83 ± 0.26
1.72 (0.38–5.59)
0.14 ± 0.34
0.34 ± 0.05

0.123
0.491†
0.028†
0.166†
0.169†
0.066†
0.240†
0.969†
0.316

Normally-distributed data are presented as Mean±SD; non-normally distributed data are presented as median (lower quartile-upper quartile) and log(10) transformed (mean ± SD) underneath. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction; GLP-1: glucagon-like peptide-1; GIP: gastric inhibitory peptide;
HOMA2-IR: updated homeostasis model assessment of insulin resistance; QUICKI: quantitative insulin-sensitivity check index. The p values in bold are < 0.05.
ǂp < 0.05 significant difference at pre-intervention between groups; †p value for test using transformed data.

Figure 3. Serum glucagon concentration [log(10) transformed] at pre- and postintervention by intervention group. Error bars represent standard error of the
mean. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction.
*p = 0.028 for group×time interaction. **p = 0.016 for pre- to post-intervention
comparison within CR group.

the CR+SR group was less than one hour and not different compared to the workday and free day difference in the CR group.
Social Jetlag of greater than 1 hour compared to less than 1 hour,
specifically, the difference in sleep schedule on weekdays and
weekend days, was previously found to be associated with increased metabolic syndrome risk and diabetes/prediabetes [58].
Therefore, the sleep timing differences were unlikely to contribute to our findings regarding group differences.
A few limitations also exist. First, only a single fasting blood
sample was collected at pre- and post-intervention. Therefore,
variables of interest, specifically glucose and its regulatory hormones, were not measured after meals or throughout 24-hour
period. We did not control the previous few nights’ sleep, which

Figure 4. Serum visfatin concentration [log(10) transformed] at pre- and postintervention by intervention group. Error bars represent standard error of the
mean. CR: calorie restriction; CR+SR: calorie restriction and sleep restriction.
*p = 0.066 for group × time interaction.

may influence the results as we discussed above. We did not use
more advanced techniques, such as the insulin clamp, which is
more sensitive to changes in glucose metabolism. Second, this
study is from a clinical trial with different primary outcomes
where blood samples were only available from a subset of participants. As such, statistical power was not determined a priori.
As a result, some findings were of medium effect sizes for the
degree of change from pre- to post-intervention, but not statistically significant.
The small sample size also did not allow us to examine
sex or racial differences within or between groups. In both
groups, 75% of participants were women; if there were sex
differences in any outcomes, the results may be more influenced by women than men participants. We also did not
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